Medication analysis of antiplatelet medication in a patient with recurrent stroke
10.3760/cma.j.cn121361-20200215-00010
- VernacularTitle:一例缺血性脑卒中复发患者的抗血小板用药分析
- Author:
Xi YANG
1
;
Li LI
;
Di CHEN
;
Mengting YANG
;
Jiangman SONG
;
Yan LIU
Author Information
1. 新疆维吾尔自治区第三人民医院药剂科，乌鲁木齐 830000
- From:
Clinical Medicine of China
2020;36(6):564-567
- CountryChina
- Language:Chinese
-
Abstract:
A case of recurrent stroke with clopidogrel secondary prevention, CYP2C19 gene testing result of " clopidogrel slow metabolism" , platelet aggregation test result of " platelet aggregation significantly inhibited" as an example, the dialectical relationship among the above gene testing, platelet aggregation test, stroke recurrence were analyzed, and the choice of antiplatelet drugs was discussed.Clopidogrel gene testing has certain guiding significance for the secondary prevention of stroke patients.Platelet aggregation test results can not comprehensively evaluate the physiology and function of platelets in vivo.In order to find a more safe, effective and reasonable antiplatelet therapy, antiplatelet therapy should be further explored and optimized.
